Latest Commercial Revenue News

Page 2 of 8
AnteoTech reported a quarter of technical milestones and commercial discussions across its battery and life sciences businesses, including new agreements with Xerabrid and Airspeeder. The company ended September with about A$11 million in cash, although an inconsistency in the Appendix 4C reconciliation needs clarification.
Victor Sage
Victor Sage
29 Oct 2026
Antimony Resources has moved its Tecomatlán plant into its first plant-scale antimony concentrate campaign, but reported only 0.9 quarters of funding at September’s cash burn. The campaign could provide the company’s first operating proof point, while also sharpening the need for additional financing or commercial revenue.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
Carnegie Clean Energy has moved its flagship CETO wave-energy project towards offshore deployment in Spain, but the technology developer ended 2026 with a wider loss, $996,347 in cash and a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
23 Oct 2026
Aeris Environmental’s FY2026 annual report pairs international commercial progress with a $5.03 million operating cash drain, $9.22 million in net liabilities and an auditor-highlighted material uncertainty over its ability to continue as a going concern. The company says it will need extended related-party loan terms and further funding while converting its technology and chemicals pipeline into recurring revenue.
Victor Sage
Victor Sage
1 Oct 2026
ClearVue Technologies reported just A$108,484 of FY2026 revenue against an A$11.86 million loss, while consuming A$8.69 million in operating cash. The solar-glazing developer says certifications, international partners and an 80-project pipeline have strengthened its platform, but the next test is converting those assets into cash revenue.
Victor Sage
Victor Sage
30 Sept 2026
FBR has cut its annual loss dramatically and moved its first Mantis welding robot into commissioning, but year-end cash of just A$27,814 leaves the company dependent on fundraising, tax funding and successful delivery. Its audited accounts flag a material uncertainty over whether the robotics developer can continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026
Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.
Victor Sage
Victor Sage
30 Sept 2026
AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.
Victor Sage
Victor Sage
30 Sept 2026
Green Technology Metals has cleared the environmental assessment for its Seymour lithium project, while a A$15.9 million capital raising leaves the company better placed to complete its definitive feasibility study. The next test is whether permitting, financing and Indigenous agreements can convert that progress into a Final Investment Decision in FY27.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Li-S Energy has narrowed its FY26 loss and reached several commercialisation milestones, including a 2C Power Cell, international shipping approvals and its first lithium foil sale. But the ASX battery developer still needs customer offtake and fresh funding before its proposed 1 GWh manufacturing expansion can become reality.
Victor Sage
Victor Sage
29 Sept 2026

Browse the archive

Full archive